Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 3P Biopharmaceuticals and Nordic Nanovector Extend Partnership | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

3P Biopharmaceuticals and Nordic Nanovector Extend Partnership

For further biopharmaceutical development of Betalutin, a non-Hodgkin lymphoma (NHL) treatment

By: Cassandra Gervolino

3P Biopharmaceuticals and Norwegian biopharmaceutical company, Nordic Nanovector, have extended their collaboration agreement for the development of Betalutin. The two companies started their collaboration in 2013 and successfully advanced Betalutin. The current agreement is consolidating the relationship describing how both companies will progress the project up to regulatory submission, including development, clinical supply and late stage activities, such as process characterization and validation. 

“Our partnership with Nordic Nanovector is a great example of how together we can achieve more than planned and succeed in the late stage of Betalutin development,” said Dámaso Molero, general manager at 3P Biopharmaceuticals. He also added “this project demonstrates how we can bring together various parties to successfully reach the project goals by using complex technologies in this challenging project.” 
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics